RxDoctor Payments Data

Diego Calonje, MD

Retina Specialist · Tucson, AZNPI 1790804961

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.6%), gifts and speaking fees — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 36.4% of the total. Reporting peaked in 2019 at $5,792 and has fallen 79.7% since, to $1,176 in 2025.

$15,688in general payments, 2019–2025

Across 119 payments — averaging $131.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$6K
  • Alimera Sciences, Inc.$3K
  • Optos, Inc.$3K
  • Alcon$2K
  • Genentech USA, Inc.$817
  • Astellas Pharma US Inc$489
  • plus $1K from 11 others

What the payments were for

  • Speaking & faculty fees$2,50016%
  • Food & beverage$7,47148%
  • Gifts$5,71736%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,688 in reported general payments places this provider in the 60th percentile of 30 retina specialist providers in Arizona.

See all retina specialist providers in Arizona

Medicare billing

Part B allowed, 2024
$2,247,772
Medicare patients
899
Services billed
36,748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluorometholone190$13,240
Prednisolone Acetate251$11,957
Ketorolac Tromethamine325$10,494
CombiganBrimonidine Tartrate/Timolol20$4,089
Latanoprost190$3,031
Ofloxacin168$1,899
Brimonidine Tartrate80$1,176
Difluprednate13$1,109
Timolol Maleate115$816
Dorzolamide Hcl36$673
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat16$296
Acetazolamide19$283
Diclofenac Sodium18$157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan$50$4,08920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 30 retina specialist providers in Arizona.

Other retina specialist in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →